DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
Angiotensin-Converting Enzyme Inhibitors
Animals
Benzazepines
/ therapeutic use
Dog Diseases
/ drug therapy
Dogs
Echocardiography
/ veterinary
Female
Heart Valve Diseases
/ drug therapy
Male
Mitral Valve
Natriuretic Peptide, Brain
Peptide Fragments
Prospective Studies
Spironolactone
/ therapeutic use
Troponin I
Dog
Heart
Heart failure
NT-proBNP
Therapy
Journal
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology
ISSN: 1875-0834
Titre abrégé: J Vet Cardiol
Pays: Netherlands
ID NLM: 101163270
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
19
04
2019
revised:
23
12
2019
accepted:
24
12
2019
pubmed:
8
2
2020
medline:
21
10
2020
entrez:
8
2
2020
Statut:
ppublish
Résumé
Efficacy of renin-angiotensin-aldosterone system (RAAS) blockade using angiotensin-converting enzyme inhibitors (ACEi) in dogs with preclinical myxomatous mitral valve disease (MMVD) is controversial. Administration of spironolactone (2-4 mg q 24 h) and benazepril (0.25-0.5 mg q 24 h) in dogs with preclinical MMVD, not receiving any other cardiac medications, delays the onset of heart failure (HF) and cardiac-related death. Moreover, it reduces the progression of the disease as indicated by echocardiographic parameters and level of cardiac biomarkers N-terminal pro brain natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI). 184 dogs with pre-clinical MMVD and left atrium-to-aortic root ratio (LA:Ao) ≥1.6 and normalized left ventricular end-diastolic diameter (LVEDDn) ≥1.7. This is a prospective, randomized, multicenter, single-blinded, placebo-controlled study. Primary outcome variable was time-to-onset of first occurrence of HF or cardiac death. Secondary end points included effect of treatment on progression of the disease based on echocardiographic and radiographic parameters, as well as variations of NT-proBNP and cTnI concentrations. The median time to primary end point was 902 days (95% confidence interval (CI) 682-not available) for the treatment group and 1139 days (95% CI 732-NA) for the control group (p = 0.45). Vertebral heart score (p = 0.05), LA:Ao (p < 0.001), LVEDDn (p < 0.001), trans-mitral E peak velocity (p = 0.011), and NT-proBNP (p = 0.037) were lower at the end of study in the treatment group. This study failed in demonstrating that combined administration of spironolactone and benazepril delays onset of HF in dogs with preclinical MMVD. However, such treatment induces beneficial effects on cardiac remodeling and these results could be of clinical relevance.
Identifiants
pubmed: 32032923
pii: S1760-2734(19)30156-0
doi: 10.1016/j.jvc.2019.12.002
pii:
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Benzazepines
0
Peptide Fragments
0
Troponin I
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Spironolactone
27O7W4T232
benazepril
UDM7Q7QWP8
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial, Veterinary
Langues
eng
Sous-ensembles de citation
IM
Pagination
34-53Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.